Patent ID: 7273613

Claim:
Diagnostic reagents for determining whether an individual has or may develop Epstein Barr Virus (EBV)-induced systemic lupus erythematosus (SLE) comprising (a) peptide antigens, which can be used to detect antibodies recognizing the Epstein-Barr virus antigen epitopes including PPPGRRP (SEQ ID NO: 1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:25), RPQKRPSC (SEQ ID NO:26), QKRPSCIGCKGTHGGTG (SEQ ID NO:27), GTGAGAGARGRGG (SEQ ID NO:99), SGGRGRGG (SEQ ID NO: 100), RGGS GGRRGRGR (SEQ ID NO: 101), RARGRGRGRGEKRPRS (SEQ ID NO:102), SSSSGSPPRRPPPGR (SEQ ID NO:103), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:104), PDVPPGAI (SEQ ID NO:33), PGAIEQGPA (SEQ ID NO:34), GPSTGPRG (SEQ ID NO:105), GQGDGGRRK (SEQ ID NO:37) DGGRRKKGGWFGKHR (SEQ ID NO:38), GKHRGQGGSN (SEQ ID NO:106), GQGGSNPK (SEQ ID NO: 107), NPKFENIA (SEQ ID NO: 108), RSHVERTT (SEQ ID NO:109), VFVYGGSKT (SEQ ID NO:110), GSKTSLYNL (SEQ ID NO: 111), GMAPGPGP (SEQ ID NO:46), PQPGPLRE (SEQ ID NO:47), CNIRVTVC (SEQ ID NO:48), RVTVCSFDDG (SEQ ID NO:49), PPWFPPMVEG (SEQ ID NO:50) and GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:98); and (b) control samples obtained from individuals with EBV infection but without evidence of SLE.